CN110607360A - Primer group and kit for assessing chronic heart failure prognosis and method for assessing chronic heart failure prognosis - Google Patents
Primer group and kit for assessing chronic heart failure prognosis and method for assessing chronic heart failure prognosis Download PDFInfo
- Publication number
- CN110607360A CN110607360A CN201910886986.XA CN201910886986A CN110607360A CN 110607360 A CN110607360 A CN 110607360A CN 201910886986 A CN201910886986 A CN 201910886986A CN 110607360 A CN110607360 A CN 110607360A
- Authority
- CN
- China
- Prior art keywords
- primer
- sequence
- downstream primer
- upstream primer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
The invention discloses a primer group and a kit for assessing chronic heart failure prognosis and a method for assessing chronic heart failure prognosis, and belongs to the field of gene detection. The primer group comprises: a first upstream primer, a first downstream primer, a second upstream primer, a second downstream primer, a third upstream primer, a third downstream primer, a fourth upstream primer, a fourth downstream primer, a fifth upstream primer, a fifth downstream primer, a sixth upstream primer, a sixth downstream primer, a seventh upstream primer, a seventh downstream primer, an eighth upstream primer, and an eighth downstream primer. The genes amplified by the primer group respectively correspond to eight risk alleles with sensitive prognosis, so that the accuracy and comprehensiveness of an evaluation result can be ensured; the method can accurately identify the mutation related to prognosis by sequencing the target amplification region and judging data, thereby judging the type and cause of diseases and providing a timely and reliable detection report for clinic.
Description
Technical Field
The invention relates to the field of gene detection, in particular to a primer group and a kit for evaluating chronic heart failure prognosis and a method for evaluating chronic heart failure prognosis.
Background
Chronic heart failure is the end state of cardiovascular disease resulting from an inability of the heart to meet the body's needs with respect to ejection fraction, the main clinical symptoms being chronic fatigue, shortness of breath, dyspnea, pulmonary congestion and edema. In the general population, women have higher morbidity than men, the prevalence rate is 9/1000, and about 400 thousands of chronic heart failure patients exist in China at present. Although new drugs and auxiliary facilities are currently used for treating chronic heart failure, the prognosis of chronic heart failure is poor, the five-year survival rate is equivalent to that of malignant tumors, and therefore, early prognosis evaluation and active treatment through the evaluation result are very important.
The existing prognosis evaluation technology of chronic heart failure mainly comprises amino terminal natriuretic peptide (NT-proBNP) detection and cardiac pulse pressure detection. NT-proBNP detection reflects the deterioration degree of the chronic heart failure by using the level of a cardiac function marker NT-proBNP, and the accuracy of the detection method is influenced by age and obesity degree although the detection method is widely applied to the evaluation of chronic heart failure. The examination of central arterial pressure can cause trauma to the patient and is generally applicable to critically ill patients with chronic heart failure.
Disclosure of Invention
In order to solve the problems in the prior art, the embodiments of the present invention provide a primer set and a kit for assessing prognosis of chronic heart failure, and a method for assessing prognosis of chronic heart failure. The technical scheme is as follows:
in one aspect, the embodiments of the present invention provide a primer set for assessing prognosis of chronic heart failure, where the primer set includes: the primer pair comprises a first upstream primer, a first downstream primer, a second upstream primer, a second downstream primer, a third upstream primer, a third downstream primer, a fourth upstream primer, a fourth downstream primer, a fifth upstream primer, a fifth downstream primer, a sixth upstream primer, a sixth downstream primer, a seventh upstream primer, a seventh downstream primer, an eighth upstream primer and an eighth downstream primer, wherein the sequence of the first upstream primer is shown as SEQ ID NO. 1 in the sequence table, the sequence of the first downstream primer is shown as SEQ ID NO. 2 in the sequence table, the sequence of the second upstream primer is shown as SEQ ID NO. 3 in the sequence table, the sequence of the second downstream primer is shown as SEQ ID NO. 4 in the sequence table, the sequence of the third upstream primer is shown as SEQ ID NO. 5 in the sequence table, the sequence of the third downstream primer is shown as SEQ ID NO. 6 in the sequence table, the sequence of the fourth upstream primer is shown as SEQ ID NO:7, and the sequence of the fourth downstream primer is shown as SEQ ID NO: as shown in figure 8, the flow of air, the sequence of the fifth upstream primer is shown as SEQ ID NO:9, and the sequence of the fifth downstream primer is shown as SEQ ID NO: as shown in figure 10 of the drawings, the sequence of the sixth upstream primer is shown as SEQ ID NO: as shown in figure 11, the first and second, the sequence of the sixth downstream primer is shown as SEQ ID NO: as shown in figure 12 of the drawings, the sequence of the seventh upstream primer is shown as SEQ ID NO: as shown in figure 13, the first and second, the sequence of the seventh downstream primer is shown as SEQ ID NO: as shown in figure 14, the first and second, the sequence of the eighth upstream primer is shown as SEQ ID NO: as shown in the drawing 15, the flow rate of the gas, the sequence of the eighth downstream primer is shown as SEQ ID NO: shown at 16.
In another aspect, the embodiments of the present invention provide a kit for assessing prognosis of chronic heart failure, the kit including: the primer set is described above.
Specifically, the kit further comprises: TaKaRa Ex Taq HS, 10 XEx Taq, dNTP mix, Primer Pool 1/2, genomic DNA and sterilized water.
In still another aspect, the present invention provides a method for assessing prognosis of chronic heart failure using the primer set, the method including:
extracting the genome DNA of a sample to be detected;
amplifying the genomic DNA through the primer group to obtain eight amplification products;
respectively carrying out Sanger sequencing on the eight amplification products to obtain eight sequencing products, wherein each sequencing product is a homozygous wild-type sequencing product, a heterozygous-type sequencing product or a homozygous mutant-type sequencing product;
assigning a value to the sequencing product, wherein when the SNP site corresponding to the amplification product is a protective factor, the homozygous wild-type sequencing product is 0, the heterozygous-type sequencing product is-1, and the homozygous mutant-type sequencing product is-2; when the SNP locus corresponding to the amplification product is a risk factor, the homozygous wild-type sequencing product is 0, the heterozygous-type sequencing product is 1, and the homozygous mutant-type sequencing product is 2;
the SNP site corresponding to the amplification product obtained by amplification of the first upstream primer, the first downstream primer, the second upstream primer, the second downstream primer, the fourth upstream primer, the fourth downstream primer, the sixth upstream primer, the sixth downstream primer, the eighth upstream primer and the eighth downstream primer is the risk factor;
the SNP site corresponding to the amplification product obtained by the amplification of the third upstream primer, the third downstream primer, the fifth upstream primer, the fifth downstream primer, the seventh upstream primer and the seventh downstream primer is the protective factor;
and adding the eight sequenced products after assignment, wherein the sum of the added products is X, if X is more than or equal to-3 and less than or equal to 0, the sample to be tested is at low risk, if X is more than or equal to 1 and less than or equal to 3, the sample to be tested is at medium risk, and if X is more than 3, the sample to be tested is at high risk.
Specifically, the procedure for amplification is: pre-denaturation at 95 ℃ for 10s and denaturation at 55 ℃ for 30s, and 35 cycles are carried out; annealing at 72 ℃ for 30 s; extension was performed at 10 ℃ for 1 h.
Specifically, the sample to be detected is a peripheral blood sample, a body fluid sample or a tissue organ sample.
The technical scheme provided by the embodiment of the invention has the following beneficial effects: the genes amplified by the primer group respectively correspond to eight risk alleles with sensitive prognosis, so that the accuracy and comprehensiveness of an evaluation result can be ensured, meanwhile, the length of an amplification product obtained by the primer group is about 500bp, and an SNP locus is designed at the middle position of the amplification product, namely about 250bp, so that the 5 'end interference result and the 3' end passivation phenomenon can be effectively prevented, the primer group can respectively and accurately amplify the SNP locus in a sample to be detected, and the amplification product can accurately reflect the prognosis condition of chronic heart failure. The eight amplification primers can be used for sequencing under a PCR amplification mode, so that the sequencing accuracy is further ensured. The method can accurately identify the mutation related to prognosis by sequencing the target amplification region and judging data, thereby judging the type and cause of diseases and providing a timely and reliable detection report for clinic. The detection method designed by the invention can achieve 100% of accuracy through sanger sequencing and typing point mutation, and the outcome of chronic heart failure has obvious heterogeneity and different characteristics of different primary factors, so that the outcome can be caused to be different.
Drawings
In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.
FIG. 1 is a typing diagram of a sequencing product corresponding to an amplification product obtained by a first upstream primer and a first downstream primer provided in the third embodiment of the present invention;
FIG. 2 is a typing diagram of a sequencing product corresponding to an amplification product obtained by a second forward primer and a second backward primer provided in the third embodiment of the present invention;
FIG. 3 is a typing diagram of a sequencing product corresponding to an amplification product obtained by a third upstream primer and a third downstream primer provided in the third embodiment of the present invention;
FIG. 4 is a typing diagram of a sequencing product corresponding to an amplification product obtained by a fourth upstream primer and a fourth downstream primer provided in the third embodiment of the present invention;
FIG. 5 is a typing diagram of a sequencing product corresponding to an amplification product obtained by a fifth upstream primer and a fifth downstream primer provided in the third embodiment of the present invention;
FIG. 6 is a typing diagram of a sequencing product corresponding to an amplification product obtained by a sixth forward primer and a sixth backward primer provided in the third embodiment of the present invention;
FIG. 7 is a typing chart of a sequencing product corresponding to an amplification product obtained by a seventh upstream primer and a seventh downstream primer provided in the third embodiment of the present invention;
FIG. 8 is a typing chart of the sequencing products corresponding to the amplification products obtained by the eighth forward primer and the eighth backward primer provided in the third embodiment of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, embodiments of the present invention will be described in detail with reference to the accompanying drawings.
Example one
The embodiment of the invention provides a primer group for evaluating chronic heart failure prognosis, which is suitable for evaluating chronic heart failure prognosis of patients with Han primary dilated cardiomyopathy and ischemic dilated cardiomyopathy, and comprises the following components in part by weight: the primer pair comprises a first upstream primer, a first downstream primer, a second upstream primer, a second downstream primer, a third upstream primer, a third downstream primer, a fourth upstream primer, a fourth downstream primer, a fifth upstream primer, a fifth downstream primer, a sixth upstream primer, a sixth downstream primer, a seventh upstream primer, a seventh downstream primer, an eighth upstream primer and an eighth downstream primer, wherein the sequence of the first upstream primer is shown as SEQ ID NO. 1 in the sequence table, the sequence of the first downstream primer is shown as SEQ ID NO. 2 in the sequence table, the sequence of the second upstream primer is shown as SEQ ID NO. 3 in the sequence table, the sequence of the second downstream primer is shown as SEQ ID NO. 4 in the sequence table, the sequence of the third upstream primer is shown as SEQ ID NO. 5 in the sequence table, the sequence of the third downstream primer is shown as SEQ ID NO. 6 in the sequence table, the sequence of the fourth upstream primer is shown as SEQ ID NO. 7 in the sequence table, the sequence of the fourth downstream primer is shown as SEQ ID NO. 8 in the sequence table, the sequence of the fifth upstream primer is shown as SEQ ID NO. 9 in the sequence table, the sequence of the fifth downstream primer is shown as SEQ ID NO. 10 in the sequence table, the sequence of the sixth upstream primer is shown as SEQ ID NO. 11 in the sequence table, the sequence of the sixth downstream primer is shown as SEQ ID NO. 12 in the sequence table, the sequence of the seventh upstream primer is shown as SEQ ID NO. 13 in the sequence table, the sequence of the seventh downstream primer is shown as SEQ ID NO. 14 in the sequence table, the sequence of the eighth upstream primer is shown as SEQ ID NO. 15 in the sequence table, and the sequence of the eighth downstream primer is shown as SEQ ID NO. 16 in the sequence table.
The genes corresponding to the primer set provided by the embodiment of the invention are shown in table 1.
Table 1 shows the genes, SNP sites and risk alleles corresponding to the primer sets provided in example one
The embodiment of the invention provides a primer group for evaluating chronic heart failure prognosis, which can accurately amplify an rs679899 SNP site corresponding to an APOB gene, an rs1042464 SNP site corresponding to an HRG gene, an rs1320191 SNP site corresponding to a TLN2 gene, an rs2301629 SNP site corresponding to an SLC25A13 gene, an rs2536512 SNP site corresponding to an SOD3 gene, an rs3134587 SNP site corresponding to a SYNM gene, an rs4273214 SNP site corresponding to an AGXT gene and an rs 33049587 SNP site corresponding to an AGXT gene in a sample to be detected respectively to obtain eight amplification products, respectively carrying out Sanger's lattice sequencing on the eight amplification products to obtain eight sequencing products, then carrying out assignment on the sequencing products according to the types of the products, adding the eight sequencing products after the assignment, judging the sample to be detected to be low risk, medium risk or high risk according to the addition, wherein the genes amplified by the primer group respectively correspond to eight risk alleles sensitive prognosis, the accuracy and comprehensiveness of the evaluation result can be ensured, meanwhile, the length of the amplification product obtained by the primer group is about 500bp, and the SNP locus is designed in the middle position of the amplification product, namely about 250bp, so that the interference result of the 5 'end and the passivation phenomenon of the 3' end can be effectively prevented, the primer group can respectively and accurately amplify the SNP locus in the sample to be detected, and the amplification product can accurately reflect the prognosis condition of chronic heart failure. The eight amplification primers can be used for sequencing under a PCR amplification mode, so that the sequencing accuracy is further ensured. Meanwhile, the length of an amplification product obtained by the primer group is about 500bp, so that the whole sequencing reaction and data analysis and interpretation can be finished within one day, and the evaluation timeliness is improved.
Example two
The embodiment of the invention provides a kit for evaluating prognosis of chronic heart failure, which comprises: the first embodiment provides a primer set.
Specifically, the kit further comprises: TaKaRa Ex Taq HS, 10 XEx Taq, dNTP mix, Primer Pool 1/2, genomic DNA and sterilized water.
The embodiment of the invention provides a kit for evaluating chronic heart failure prognosis, which can accurately amplify an rs679899 SNP site corresponding to an APOB gene, an rs1042464 SNP site corresponding to an HRG gene, an rs1320191 SNP site corresponding to a TLN2 gene, an rs2301629 SNP site corresponding to an SLC25A13 gene, an rs2536512 SNP site corresponding to an SOD3 gene, an rs3134587 SNP site corresponding to a SYNM gene, an rs4273214 SNP site corresponding to an AGXT gene and an rs33958047 SNP site corresponding to the AGXT gene in a sample to be detected respectively to obtain eight amplification products, perform sanger lattice sequencing on the eight amplification products respectively to obtain eight sequencing products, then assign values to the sequencing products according to the types of the products, add the eight sequencing products after assigning values, judge that the sample to be detected is low-risk, medium-risk or high-risk according to the addition, the genes amplified by the primer group correspond to eight sensitive prognosis alleles respectively, the accuracy and comprehensiveness of the evaluation result can be ensured.
EXAMPLE III
The embodiment of the invention provides a method for evaluating chronic heart failure prognosis by using the primer group provided in the first embodiment, which comprises the following steps:
patients were hospitalized for diagnosis of dilated cardiomyopathy, coronary atherosclerosis, a history of cardiac arrhythmia, negative diabetes, a history of hypertension, smokeless alcohol addiction, height 175cm, weight 53kg, hospitalization blood pressure 123/81mmHg, heart rate 88 times/minute, New York Heart function Classification (NYHA)4, fasting plasma glucose 4.66(mmol/L), ALT 55(U/L), AST36(U/L), TC 4.11(mmol/L), TG1.08(mmol/L), Cr 76(umol/L), HDL 1.49(mmol/L), LDL2.31(mmol/L), NT-proBNP 50ng/L, cardiac ultrasonography left ventricular ejection fraction 25%, left ventricular internal diameter 77cm, left atrial internal diameter 45cm, ventricular septum 9cm, left ventricular posterior wall 8 forehead cm. The medicines for patients to take for a long time include metoprolol tartrate tablets, digoxin, furosemide tablets, spironolactone tablets and captopril tablets. The patient was assessed as at intermediate risk via a central arterial pressure test.
Specifically, the sample to be tested may be a peripheral blood sample, a body fluid sample or a tissue organ sample of a patient.
In this embodiment, the sample to be tested is a peripheral blood sample of a patient, and 5mL of fasting venous blood of the patient is taken on the day of admission, subjected to EDTA anticoagulation treatment, and stored at 4 ℃.
The genomic DNA of the peripheral blood of the patient was extracted using a blood DNA extraction kit provided by Tiangen Biochemical technology (Beijing) Ltd and stored at-20 ℃.
Amplifying the genome DNA through a primer group to obtain eight amplification products;
specifically, the amplification system is shown in table 2, specifically as follows:
TABLE 2 amplification System
Specifically, the procedure for amplification is: pre-denaturation at 95 ℃ for 10s and denaturation at 55 ℃ for 30s, and 35 cycles are carried out; annealing at 72 ℃ for 30 s; extension was performed at 10 ℃ for 1 h.
Respectively carrying out Sanger (Sanger) sequencing on the eight amplification products to obtain eight sequencing products, wherein each sequencing product is a homozygous wild-type sequencing product, a heterozygous-type sequencing product or a homozygous mutant-type sequencing product;
assigning the sequencing product, wherein when the SNP site corresponding to the amplification product is a protective factor, the homozygous wild-type sequencing product is 0, the heterozygous-type sequencing product is-1, and the homozygous mutant-type sequencing product is-2; when SNP loci corresponding to the amplification products are risk factors, the homozygous wild type sequencing product is 0, the heterozygous type sequencing product is 1, and the homozygous mutant type sequencing product is 2; the eight sequencing products of the sample to be tested provided by the embodiment of the invention are respectively shown in fig. 1 to 8.
SNP sites corresponding to amplification products obtained by amplification of a first upstream primer, a first downstream primer, a second upstream primer, a second downstream primer, a fourth upstream primer, a fourth downstream primer, a sixth upstream primer, a sixth downstream primer, an eighth upstream primer and an eighth downstream primer are risk factors;
SNP sites corresponding to amplification products obtained by amplification of the third upstream primer, the third downstream primer, the fifth upstream primer, the fifth downstream primer, the seventh upstream primer and the seventh downstream primer are protective factors;
and adding the eight assigned sequencing products, wherein the sum of the addition is X, if X is more than or equal to-3 and less than or equal to 0, the sample to be detected is at low risk, if X is more than or equal to 1 and less than or equal to 3, the sample to be detected is at medium risk, and if X is more than 3, the sample to be detected is at high risk.
In this embodiment, the assignment of the sample to be tested according to the sequence of the primers in the primer set is: 2. 0, -2, 1, -1, 2, 1 and 0, adding the eight assigned sequencing products, and calculating to obtain the sum X of the added products as 3, namely that X falls into the medium risk range, thus the sample to be detected is medium risk. This is consistent with the central arterial pressure test results of the patients, and it can be seen that the method for assessing chronic heart failure prognosis provided by the embodiment of the present invention is accurate.
The embodiment of the invention provides a method for evaluating prognosis of chronic heart failure, which can accurately identify mutation related to prognosis by sequencing a target amplification region and judging data, thereby judging the type and cause of diseases and providing a timely and reliable detection report for clinic. The detection method designed by the invention can achieve 100% of accuracy through sanger sequencing and typing point mutation, and the outcome of chronic heart failure has obvious heterogeneity and different characteristics of different primary factors, so that the outcome can be caused to be different.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Sequence listing
<110> affiliated Tongji hospital of Tongji medical college of Huazhong university of science and technology
<120> primer set and kit for assessing prognosis of chronic heart failure and method for assessing prognosis of chronic heart failure
<160> 16
<170> SIPOSequenceListing 1.0
<210> 1
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gctgtacaaa atgggctaga gaac 24
<210> 2
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
tggaattcca accctaggtt tt 22
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
tgggcactta agaaggcgag 20
<210> 4
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
tttcccattc acattttgct gc 22
<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
caaaaaccag acgtgtagac acct 24
<210> 6
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ctttgtcact tgtctcagag gacg 24
<210> 7
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
ctgatgcggc tgttagaagt tagt 24
<210> 8
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
tatcacattt ttggatgtcc actg 24
<210> 9
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
catgctggcg ctactgtgt 19
<210> 10
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
caggtccccg aactggtg 18
<210> 11
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
gggaaagaaa acagaagtga aagc 24
<210> 12
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
gaactgcttc aggatactgg taac 24
<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
ctgccccaag aagaagctgt 20
<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
ctgcagctca tttggaaggc 20
<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
gcagtgccca gatttgaacc 20
<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
tcctttcctg gtcactcctt g 21
Claims (6)
1. A primer set for assessing prognosis of chronic heart failure, wherein the primer set comprises: the primer pair comprises a first upstream primer, a first downstream primer, a second upstream primer, a second downstream primer, a third upstream primer, a third downstream primer, a fourth upstream primer, a fourth downstream primer, a fifth upstream primer, a fifth downstream primer, a sixth upstream primer, a sixth downstream primer, a seventh upstream primer, a seventh downstream primer, an eighth upstream primer and an eighth downstream primer, wherein the sequence of the first upstream primer is shown as SEQ ID NO. 1 in the sequence table, the sequence of the first downstream primer is shown as SEQ ID NO. 2 in the sequence table, the sequence of the second upstream primer is shown as SEQ ID NO. 3 in the sequence table, the sequence of the second downstream primer is shown as SEQ ID NO. 4 in the sequence table, the sequence of the third upstream primer is shown as SEQ ID NO. 5 in the sequence table, the sequence of the third downstream primer is shown as SEQ ID NO. 6 in the sequence table, the sequence of the fourth upstream primer is shown as SEQ ID NO:7, and the sequence of the fourth downstream primer is shown as SEQ ID NO: as shown in figure 8, the flow of air, the sequence of the fifth upstream primer is shown as SEQ ID NO:9, and the sequence of the fifth downstream primer is shown as SEQ ID NO: as shown in figure 10 of the drawings, the sequence of the sixth upstream primer is shown as SEQ ID NO: as shown in figure 11, the first and second, the sequence of the sixth downstream primer is shown as SEQID NO:12, and the sequence of the seventh upstream primer is shown as SEQ ID NO: as shown in figure 13, the first and second, the sequence of the seventh downstream primer is shown as SEQ ID NO: as shown in figure 14, the first and second, the sequence of the eighth upstream primer is shown as SEQ ID NO: as shown in the drawing 15, the flow rate of the gas, the sequence of the eighth downstream primer is shown as SEQ ID NO: shown at 16.
2. A kit for assessing prognosis of chronic heart failure, the kit comprising: the primer set of claim 1.
3. The kit of claim 2, further comprising: TaKaRa Ex Taq HS, 10 XEx Taq, dNTP mix, Primer Pool 1/2, genomic DNA and sterilized water.
4. A method for assessing prognosis of chronic heart failure using the primer set according to claim 1, wherein the method comprises:
extracting the genome DNA of a sample to be detected;
amplifying the genomic DNA through the primer group to obtain eight amplification products;
respectively carrying out Sanger sequencing on the eight amplification products to obtain eight sequencing products, wherein each sequencing product is a homozygous wild-type sequencing product, a heterozygous-type sequencing product or a homozygous mutant-type sequencing product;
assigning a value to the sequencing product, wherein when the SNP site corresponding to the amplification product is a protective factor, the homozygous wild-type sequencing product is 0, the heterozygous-type sequencing product is-1, and the homozygous mutant-type sequencing product is-2; when the SNP locus corresponding to the amplification product is a risk factor, the homozygous wild-type sequencing product is 0, the heterozygous-type sequencing product is 1, and the homozygous mutant-type sequencing product is 2;
the SNP site corresponding to the amplification product obtained by amplification of the first upstream primer, the first downstream primer, the second upstream primer, the second downstream primer, the fourth upstream primer, the fourth downstream primer, the sixth upstream primer, the sixth downstream primer, the eighth upstream primer and the eighth downstream primer is the risk factor;
the SNP site corresponding to the amplification product obtained by the amplification of the third upstream primer, the third downstream primer, the fifth upstream primer, the fifth downstream primer, the seventh upstream primer and the seventh downstream primer is the protective factor;
and adding the eight sequenced products after assignment, wherein the sum of the added products is X, if X is more than or equal to-3 and less than or equal to 0, the sample to be tested is at low risk, if X is more than or equal to 1 and less than or equal to 3, the sample to be tested is at medium risk, and if X is more than 3, the sample to be tested is at high risk.
5. The method of claim 4, wherein the procedure for amplification is: pre-denaturation at 95 ℃ for 10s and denaturation at 55 ℃ for 30s, and 35 cycles are carried out; annealing at 72 ℃ for 30 s; extension was performed at 10 ℃ for 1 h.
6. The method of claim 4, wherein the test sample is a peripheral blood sample, a body fluid sample, or a tissue organ sample.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910886986.XA CN110607360A (en) | 2019-09-19 | 2019-09-19 | Primer group and kit for assessing chronic heart failure prognosis and method for assessing chronic heart failure prognosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910886986.XA CN110607360A (en) | 2019-09-19 | 2019-09-19 | Primer group and kit for assessing chronic heart failure prognosis and method for assessing chronic heart failure prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110607360A true CN110607360A (en) | 2019-12-24 |
Family
ID=68891819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910886986.XA Pending CN110607360A (en) | 2019-09-19 | 2019-09-19 | Primer group and kit for assessing chronic heart failure prognosis and method for assessing chronic heart failure prognosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110607360A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111440862A (en) * | 2020-05-19 | 2020-07-24 | 华中科技大学同济医学院附属同济医院 | Primer group, kit and method for evaluating prognosis of chronic heart failure patient |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002040500A2 (en) * | 2000-11-16 | 2002-05-23 | Immundiagnostik Ag | Method of prognosis and diagnosis of congestive heart failure |
| US20050196794A1 (en) * | 2004-02-18 | 2005-09-08 | Peter Nurnberg | Use of haplotypes and SNPs in lipid-relevant genes for the analysis and diagnosis of cardiovascular disease |
| US20120141450A1 (en) * | 2009-06-09 | 2012-06-07 | Gendiag.Exe, S.L. | Risk markers for cardiovascular disease |
| CN104988216A (en) * | 2015-06-08 | 2015-10-21 | 汪道文 | Serum miRNA relevant to chronic heart failure and application of serum miRNA |
| CN105586406A (en) * | 2016-01-15 | 2016-05-18 | 汪道文 | Method for detecting gene polymorphism of ADRB1 and GRK5 |
| CN109799330A (en) * | 2019-02-22 | 2019-05-24 | 华中科技大学同济医学院附属同济医院 | The application of neuraminic acid and neuraminidase inhibitor in chronic heart failure |
| CN110106251A (en) * | 2019-06-10 | 2019-08-09 | 华中科技大学同济医学院附属同济医院 | Combination, kit and the chip of mononucleotide polymorphism site for incidence of coronary heart disease risk profile |
| CN110161242A (en) * | 2019-05-23 | 2019-08-23 | 华中科技大学同济医学院附属同济医院 | Application of EETs, sEH, sEH inhibitor in chronic heart failure |
-
2019
- 2019-09-19 CN CN201910886986.XA patent/CN110607360A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002040500A2 (en) * | 2000-11-16 | 2002-05-23 | Immundiagnostik Ag | Method of prognosis and diagnosis of congestive heart failure |
| US20050196794A1 (en) * | 2004-02-18 | 2005-09-08 | Peter Nurnberg | Use of haplotypes and SNPs in lipid-relevant genes for the analysis and diagnosis of cardiovascular disease |
| US20120141450A1 (en) * | 2009-06-09 | 2012-06-07 | Gendiag.Exe, S.L. | Risk markers for cardiovascular disease |
| CN104988216A (en) * | 2015-06-08 | 2015-10-21 | 汪道文 | Serum miRNA relevant to chronic heart failure and application of serum miRNA |
| CN105586406A (en) * | 2016-01-15 | 2016-05-18 | 汪道文 | Method for detecting gene polymorphism of ADRB1 and GRK5 |
| CN109799330A (en) * | 2019-02-22 | 2019-05-24 | 华中科技大学同济医学院附属同济医院 | The application of neuraminic acid and neuraminidase inhibitor in chronic heart failure |
| CN110161242A (en) * | 2019-05-23 | 2019-08-23 | 华中科技大学同济医学院附属同济医院 | Application of EETs, sEH, sEH inhibitor in chronic heart failure |
| CN110106251A (en) * | 2019-06-10 | 2019-08-09 | 华中科技大学同济医学院附属同济医院 | Combination, kit and the chip of mononucleotide polymorphism site for incidence of coronary heart disease risk profile |
Non-Patent Citations (4)
| Title |
|---|
| HE GH等: "Associations of Polymorphisms in HRH2, HRH3, DAO,and HNMT Genes with Risk of Chronic Heart Failure", 《BIOMED RES INT》 * |
| HU D等: "A common variant of RIP3 promoter region is associated with poor prognosis in heart failure patients by influencing SOX17 binding", 《J CELL MOL MED》 * |
| LI S等: "Genetic risk scores to predict the prognosis of chronic heart failure patients in Chinese Han", 《J CELL MOL MED》 * |
| LIU C等: "Polymorphisms in ApoB gene are associated with risk of myocardial infarction and serum ApoB levels in a Chinese population", 《INT J CLIN EXP MED》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111440862A (en) * | 2020-05-19 | 2020-07-24 | 华中科技大学同济医学院附属同济医院 | Primer group, kit and method for evaluating prognosis of chronic heart failure patient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230203573A1 (en) | Methods for detection of donor-derived cell-free dna | |
| JP6092655B2 (en) | Classification of test body fluid samples | |
| Mouton et al. | MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients | |
| CN108456726A (en) | Spinal muscular atrophy genetic test probe, primer and kit | |
| CN110982890A (en) | Reagent for predicting children Kawasaki disease treatment responsiveness and application thereof | |
| CN104762368B (en) | A kind of kit for being used to aid in the prediction patients with esophageal squamous cell carcinoma post-operative survival rates time | |
| CN114085903A (en) | Primer pair probe combination product for detecting mitochondria 3243A & gtG mutation, kit and detection method thereof | |
| CN110607360A (en) | Primer group and kit for assessing chronic heart failure prognosis and method for assessing chronic heart failure prognosis | |
| US20110184712A1 (en) | Predictive models and methods for diagnosing and assessing coronary artery disease | |
| CN115418397B (en) | Biomarker for auxiliary diagnosis of dilated cardiomyopathy and application thereof | |
| CN110106251B (en) | Combination, kit and chip of single nucleotide polymorphism sites for predicting coronary heart disease onset risk | |
| KR101979633B1 (en) | SNP markers for metabolic syndrome and use thereof | |
| CN109988830A (en) | A kind of lncRNA and its application for sepsis markers | |
| TW201140051A (en) | Gene group test structure | |
| CN113322317A (en) | Primer pair, probe set and kit for mitochondrial obesity gene mutation detection | |
| CN113025707A (en) | Application of biomarker in preparation of product for diagnosing damp-heat spleen-encumbering type 2 diabetes and kit | |
| CN111440862A (en) | Primer group, kit and method for evaluating prognosis of chronic heart failure patient | |
| TWI740533B (en) | Method for estimating a risk for a subject suffering from encapsulating peritoneal sclerosis, analyzer and kit thereof | |
| CN111566229A (en) | Breast cancer molecular typing and distant metastasis risk gene group, diagnosis product and application | |
| CN113817817B (en) | Method for diagnosing allergic airway inflammation | |
| CN113801928A (en) | Method for assessing risk of individuals suffering from peritoneal sclerosis, analyzer thereof and kit thereof | |
| CN107164550A (en) | A kind of reagent for detecting myocardial infarction and its application | |
| CN107164546A (en) | MiRNA, composition and its application in diagnosing the illness | |
| CN107365834A (en) | Detect the kit of colorectal cancer patients PIK3CA gene mutations | |
| CN114525332A (en) | Diagnosis marker, scoring model and diagnosis product for dilated cardiomyopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191224 |
|
| WD01 | Invention patent application deemed withdrawn after publication |